SCHEMBL1996203

SCHEMBL1996203

O=Cc1cccc(-c2ccc(CN3CC(=O)NC3=O)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
ENPP2 Q13822 1/20 0.41
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
EPHX2 P34913 1/20 0.40
CRBN Q96SW2 2/20 0.40
DDB1 Q16531 1/20 0.40
GRM2 Q14416 4/20 0.39
MCHR1 Q99705 1/20 0.36
GAA P10253 1/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001787 0.82 ENPP2 (0.57) ENPP2EPHX2CRBNDDB1GRM2
SCHEMBL1997253 0.74 MAT2A (0.38) ENPP2EPHX2CRBNDDB1
SCHEMBL31528292 0.74 CYP2D6 (0.66) TRIM24TRIM33CA12CA1CA2
SCHEMBL1996322 0.74 CNR1 (0.44) EPHX2CRBNDDB1MCHR1
SCHEMBL20189142 0.73 EPHX2 (0.47) CA2ENPP2EPHX2CRBNDDB1
SCHEMBL1011633 0.72 DDB1 (0.69) ENPP2EPHX2CRBNDDB1GAA
SCHEMBL9850086 0.72 DDB1 (0.69) ENPP2EPHX2CRBNDDB1GAA
SCHEMBL11770226 0.72 TRIM24 (0.71) TRIM24TRIM33CA12CA1CA2
SCHEMBL9164640 0.71 EPHX2 (0.49) EPHX2CRBNDDB1GRM2GAA
SCHEMBL9850110 0.71 DDB1 (0.67) ENPP2EPHX2CRBNDDB1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 TRIM24 2544/4885TRIM33 2835/4885CA12 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.